Tyler C. Glass

Tyler C. Glass

Senior Associate Corporate & Finance

Philadelphia

+1 267 675 4697

[email protected]

Tyler C. Glass

Overview
Experience
Credentials
Insights and events

Tyler Glass believes that good lawyering starts with a good attitude — which is why he approaches every client engagement with initiative, curiosity, and the occasional well‑timed dad joke.

As a securities and public company advisory associate in Philadelphia, Tyler focuses on guiding primarily life sciences companies through a wide range of corporate and securities matters. His experience includes advising on 1933 and 1934 Act reporting, Section 16 and Section 13 compliance, Nasdaq and NYSE listing issues, and capital markets transactions such as ATMs, RDOs, CMPOs, and PIPEs. He has significant experience preparing and reviewing SEC disclosures, including Forms 8‑K, 10‑Q, and 10‑K, as well as proxy statements, registration statements, board and committee resolutions, governance presentations and policies, and press releases. Tyler regularly counsels senior executives, boards of directors, finance teams, and investor relations teams on securities law, corporate governance, transactional matters, and other complex issues.

Drawn early to both the legal profession and the world of business and finance, Tyler is grateful to work at the intersection of those interests. He approaches each engagement as a lifelong learner — unafraid to ask questions, dig into the details, and understand the nuances of his clients’ goals.

During law school, Tyler served as a staff editor on the Temple Law Review. He also gained experience as a summer associate at Hogan Lovells and as a judicial intern for the Honorable Marilyn Heffley of the U.S. District Court for the Eastern District of Pennsylvania.

Representative experience

Perspective Therapeutics (NYSE American: CATX), a radiopharmaceutical company, on its US$175m underwritten offering of common stock and pre-funded warrants led by Piper Sandler and UBS.

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), a late-stage clinical biopharmaceutical company, on its US$259m underwritten follow-on offering of common shares.

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company, on its US$57.5m underwritten follow-on offering of common stock and pre-funded warrants.

Grace Therapeutics, Inc. (Nasdaq: GRCE), a late-stage, biopharma company, on its private placement offering of common stock, pre-funded warrants and common warrants.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company, on its back-to-back registered direct offerings and concurrent private placements of common stock and warrants.

Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its 1-for-10 reverse stock split.

Portage Biotech Inc. (Nasdaq: PRTG), a clinical-stage immuno-oncology company, on its 1-for-20 reverse stock split.

Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its US$80m underwritten offering of common stock and pre-funded warrants.

Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its US$87.4m private placement financing led by Oppenheimer & Co.

Perspective Therapeutics (NYSE American: CATX), a clinical-stage radiopharmaceutical company, on its US$69m underwritten public follow-on offering and concurrent US$20.8m private placement.

Portage Biotech Inc. (Nasdaq: PRTG), a clinical-stage immuno-oncology company, on a registered direct offering and a concurrent private placement led by H.C. Wainwright.

Sesen Bio (Nasdaq: SESN), a clinical life sciences company, on its US$36m reverse merger involving special cash and contingent value right dividends and activist shareholder involvement.

Marinus Pharmaceuticals (Nasdaq: MRNS) on its US$60m underwritten public offering of equity securities through a syndicate of underwriters led by SVB Securtities, RBC Securities and Cantor.

Several clinical-stage life sciences companies in at-the-market equity offerings led by RBC Capital Markets, Jefferies, JMP Securities, and Cantor Fitzgerald.

Regular corporate governance and securities advice to a wide variety of life sciences public companies.

NextNav Inc. (Nasdaq: NN), a leader in next-generation GPS, on its business combination with Spartacus Acquisition Corp., a special purpose acquisition company.